Adult T-cell leukemia medical therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 3: | Line 3: | ||
{{CMG}} {{AE}} {{HL}} | {{CMG}} {{AE}} {{HL}} | ||
==Overview== | ==Overview== | ||
The optimal therapy for adult T-cell leukemia depends on the clinical variant of the disease. Chronic and smoldering adult T-cell leukemia patients are usually managed by either observation, [[skin]] directed therapies, or a combination of [[zidovudine]] and [[interferon]] therapy. Acute adult T-cell leukemia patients are usually managed by either [[chemotherapy]], supportive care, allogeneic [[stem cell transplant]], or a combination of [[zidovudine]] and [[interferon]] therapy. | The optimal therapy for adult T-cell leukemia depends on the clinical variant of the disease. Chronic and smoldering adult T-cell leukemia patients are usually managed by either observation, [[skin]] directed therapies, or a combination of [[zidovudine]] and [[interferon]] therapy. Acute adult T-cell leukemia patients are usually managed by either [[chemotherapy]], supportive care, allogeneic [[stem cell transplant]], or a combination of [[zidovudine]] and [[interferon]] therapy. The first line [[Chemotherapy|chemotherapeutic]] regimens used for the initial management of adult T-cell leukemia include [[CHOP]], [[CHOEP regimen|CHOEP]], or [[DA-EPOCH regimen|Dose-adjusted EPOCH]]. Second line [[Chemotherapy|chemotherapeutic]] agents might be [[DHAP regimen|DHAP]], [[ESHAP regimen|ESHAP]], GDP, [[GemOx-R regimen|GemOx]], or [[ICE-R regimen|ICE]]. | ||
==Medical Therapy== | ==Medical Therapy== | ||
The following are the various options for management of adult-T cell leukemia according to the National Comprehensive Cancer Network (NCCN) guidelines:<ref name="NCCN">Adult T-Cell Leukemia/Lymphoma. NCCN Guidelines Version 2 (2015) http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf Accessed on January, 25 2016</ref><ref name="HermineBouscary19952">{{cite journal|last1=Hermine|first1=Olivier|last2=Bouscary|first2=Didier|last3=Gessain|first3=Antoine|last4=Turlure|first4=Pascal|last5=Leblond|first5=Veronique|last6=Franck|first6=Nathalie|last7=Buzyn-Veil|first7=Agnes|last8=Rio|first8=Bernard|last9=Macintyre|first9=Elisabeth|last10=Dreyfus|first10=Francois|last11=Bazarbachi|first11=Ali|title=Treatment of Adult T-Cell Leukemia-Lymphoma with Zidovudine and Interferon Alfa|journal=New England Journal of Medicine|volume=332|issue=26|year=1995|pages=1749–1751|issn=0028-4793|doi=10.1056/NEJM199506293322604}}</ref> | The following are the various options for management of adult-T cell leukemia according to the National Comprehensive Cancer Network (NCCN) guidelines:<ref name="NCCN">Adult T-Cell Leukemia/Lymphoma. NCCN Guidelines Version 2 (2015) http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf Accessed on January, 25 2016</ref><ref name="HermineBouscary19952">{{cite journal|last1=Hermine|first1=Olivier|last2=Bouscary|first2=Didier|last3=Gessain|first3=Antoine|last4=Turlure|first4=Pascal|last5=Leblond|first5=Veronique|last6=Franck|first6=Nathalie|last7=Buzyn-Veil|first7=Agnes|last8=Rio|first8=Bernard|last9=Macintyre|first9=Elisabeth|last10=Dreyfus|first10=Francois|last11=Bazarbachi|first11=Ali|title=Treatment of Adult T-Cell Leukemia-Lymphoma with Zidovudine and Interferon Alfa|journal=New England Journal of Medicine|volume=332|issue=26|year=1995|pages=1749–1751|issn=0028-4793|doi=10.1056/NEJM199506293322604}}</ref> | ||
| Line 37: | Line 37: | ||
===Management of Acute Adult T-cell Leukemia=== | ===Management of Acute Adult T-cell Leukemia=== | ||
* The first line chemotherapeutic regimens used for the initial management of adult T-cell leukemia include: | * The first line [[Chemotherapeutic agent|chemotherapeutic]] regimens used for the initial management of adult T-cell leukemia include: | ||
:* [[Cyclophosphamide]] {{and}} [[doxorubicin]] {{and}} [[vincristine]] {{and}} [[prednisone]] ([[CHOP]]) | :* [[Cyclophosphamide]] {{and}} [[doxorubicin]] {{and}} [[vincristine]] {{and}} [[prednisone]] ([[CHOP]]) | ||
:* [[Cyclophosphamide]] {{and}} [[Doxorubicin hydrochloride|doxorubicin]] {{and}} [[Vincristine sulfate|vincristine]] {{and}} [[etoposide]] {{and}} [[prednisone]] ([[CHOEP regimen|CHOEP]]) | :* [[Cyclophosphamide]] {{and}} [[Doxorubicin hydrochloride|doxorubicin]] {{and}} [[Vincristine sulfate|vincristine]] {{and}} [[etoposide]] {{and}} [[prednisone]] ([[CHOEP regimen|CHOEP]]) | ||
Revision as of 16:14, 3 February 2019
|
Adult T-cell leukemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Adult T-cell leukemia medical therapy On the Web |
|
American Roentgen Ray Society Images of Adult T-cell leukemia medical therapy |
|
Risk calculators and risk factors for Adult T-cell leukemia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]
Overview
The optimal therapy for adult T-cell leukemia depends on the clinical variant of the disease. Chronic and smoldering adult T-cell leukemia patients are usually managed by either observation, skin directed therapies, or a combination of zidovudine and interferon therapy. Acute adult T-cell leukemia patients are usually managed by either chemotherapy, supportive care, allogeneic stem cell transplant, or a combination of zidovudine and interferon therapy. The first line chemotherapeutic regimens used for the initial management of adult T-cell leukemia include CHOP, CHOEP, or Dose-adjusted EPOCH. Second line chemotherapeutic agents might be DHAP, ESHAP, GDP, GemOx, or ICE.
Medical Therapy
The following are the various options for management of adult-T cell leukemia according to the National Comprehensive Cancer Network (NCCN) guidelines:[1][2]
- The optimal therapy for adult T-cell leukemia depends on the clinical variant of the disease.
- Chronic and smoldering adult T-cell leukemia patients are usually managed by either observation, skin directed therapies, or a combination of zidovudine and interferon therapy.[3]
- Acute adult T-cell leukemia patients are usually managed by either chemotherapy, supportive care, allogeneic stem cell transplant, or a combination of zidovudine and interferon therapy.
- Adult T-cell lymphoma patients are usually managed by either chemotherapy, supportive care, or allogeneic stem cell transplant.
Management of Chronic/Smoldering Adult T-cell Leukemia
- Patients may be managed by observation and close follow-up for any symptomatic deterioration. Follow up of such patients must include:
- A complete history and physical examination
- Serum calcium level
- Blood urea nitrogen
- Serum creatinine level
- Serum LDH
- Chest and abdominal CT scan
- Skin directed therapies for the management of localized cutaneous lesions among such patients may include:
- Topical corticosteroids
- Topical chemotherapy (mechlorethamine)
- Local radiotherapy (8–36 Gy)
- Topical retinoids (bexarotene, tazarotene)
- Phototherapy (UVB, NB-UVB for management of patch/thin plaques; PUVA for management of thicker plaques)
- Topical imiquimod
- Zidovudine and interferon combination therapy:
- Chronic/smoldering adult T-cell leukemia patients should be evaluated for response after two months of initiating the combination therapy.
- Patients who respond to the therapy should be continued on zidovudine and interferon therapy.
- Patients who did not respond to the therapy, should be managed by either chemotherapy or supportive care depending on the patients preference.
- The criteria for complete remission of adult T-cell leukemia patients includes:
- Absence of lymphadenopathy
- Absence of hepatomegaly and splenomegaly
- Absence of cutaneous lesions
- Absence of malignant cells on peripheral blood smear
- Absence of malignant cells on bone marrow biopsy
Management of Acute Adult T-cell Leukemia
- The first line chemotherapeutic regimens used for the initial management of adult T-cell leukemia include:
- Cyclophosphamide AND doxorubicin AND vincristine AND prednisone (CHOP)
- Cyclophosphamide AND doxorubicin AND vincristine AND etoposide AND prednisone (CHOEP)
- Etoposide AND prednisone AND vincristine AND cyclophosphamide AND doxorubicin (Dose-adjusted EPOCH)
- Cyclophosphamide AND vincristine AND doxorubicin AND dexamethasone (HyperCVAD) alternating with high-dose methotrexate and cytarabine
- Consider allogeneic stem cell transplantation for patients who respond to first line chemotherapeutic agents.
- Patients who do not respond to the initial chemotherapeutic regimens may be managed by other second line chemotherapeutic agents such as:
- Bendamustine
- Belinostat
- Dexamethasone AND cisplatin AND cytarabine (DHAP)
- Etoposide AND methylprednisolone AND cytarabine AND cisplatin (ESHAP)
- Gemcitabine AND dexamethasone AND cisplatin (GDP)
- Gemcitabine AND oxaliplatin (GemOx)
- Ifosfamide AND carboplatin AND etoposide (ICE)
- Pralatrexate
- Romidepsin
- Consider allogeneic stem cell transplantation for patients who respond to second line chemotherapeutic agents.
- Zidovudine and interferon combination therapy:
- Chronic/smoldering adult T-cell leukemia patients should be evaluated for response after two months of initiating the combination therapy.
- Patients who respond to the therapy may be further managed by either allogeneic stem cell transplantation or continue on zidovudine and interferon combination therapy.
- Patients who did not respond to the therapy, should be managed by either chemotherapy or supportive care depending on the patients preference.
Supportive Therapy
Opportunistic Infections Prophylaxis
- Sulfamethoxazole/trimethoprim prophylaxis is recommended among adult T-cell leukemia patients to protect against opportunistic infections.
References
- ↑ Adult T-Cell Leukemia/Lymphoma. NCCN Guidelines Version 2 (2015) http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf Accessed on January, 25 2016
- ↑ Hermine, Olivier; Bouscary, Didier; Gessain, Antoine; Turlure, Pascal; Leblond, Veronique; Franck, Nathalie; Buzyn-Veil, Agnes; Rio, Bernard; Macintyre, Elisabeth; Dreyfus, Francois; Bazarbachi, Ali (1995). "Treatment of Adult T-Cell Leukemia-Lymphoma with Zidovudine and Interferon Alfa". New England Journal of Medicine. 332 (26): 1749–1751. doi:10.1056/NEJM199506293322604. ISSN 0028-4793.
- ↑ Hermine, Olivier; Bouscary, Didier; Gessain, Antoine; Turlure, Pascal; Leblond, Veronique; Franck, Nathalie; Buzyn-Veil, Agnes; Rio, Bernard; Macintyre, Elisabeth; Dreyfus, Francois; Bazarbachi, Ali (1995). "Treatment of Adult T-Cell Leukemia-Lymphoma with Zidovudine and Interferon Alfa". New England Journal of Medicine. 332 (26): 1749–1751. doi:10.1056/NEJM199506293322604. ISSN 0028-4793.